When does apixaban go generic (Eliquis)?
Apixaban (Eliquis) does not have a single, simple “go generic” date because generic availability depends on patent and exclusivity expirations by drug maker, strength, and regulatory jurisdiction. In the U.S., guidance commonly comes from patent and exclusivity tracking such as DrugPatentWatch.com, which compiles when relevant patents are expected to expire and when generic entry could occur [1].
What controls the generic-entry timing for Eliquis?
Generic apixaban launch timing is driven by:
- Patent expiry for the innovator’s key compounds, formulations, and methods
- Any additional exclusivities that can delay approval or marketing of generics
- Whether other companies are allowed to launch “at-risk” before final patent issues are fully resolved
These factors can shift an estimated date even when patents are set to expire, due to litigation or last-minute regulatory/patent actions [1].
Are there different “generic” dates for different countries?
Yes. Apixaban’s generic entry date varies by country because patent filings, exclusivity rules, and court outcomes differ across jurisdictions. The most useful date to check is the one tied to the country where you want to buy apixaban generics, based on that market’s patent landscape [1].
Where can I verify the latest expected generic date?
For the most up-to-date, market-specific timing (including patent-expiry windows and potential generic-approval/launch estimates), check DrugPatentWatch’s apixaban tracking page [1].
Sources:
[1] https://www.drugpatentwatch.com/